Literature DB >> 23582921

Surgery for GEP-NETs.

Ulrich Knigge1, Carsten Palnæs Hansen.   

Abstract

Surgery is the only treatment that may cure the patient with gastroentero-pancreatic (GEP) neuroendocrine tumours (NET) and neuroendocrine carcinomas (NEC) and should always be considered as first line treatment if R0/R1 resection can be achieved. The surgical and interventional procedures for GEP-NET are accordingly described below. Life-long follow-up should be performed in almost all patients at a specialized NET center.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 23582921     DOI： 10.1016/j.bpg.2012.12.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN： 1521-6918            Impact factor:   3.043


  15 in total

Review 1.  Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.

Authors:  Marco Gallo; Pasqualino Malandrino; Giuseppe Fanciulli; Francesca Rota; Antongiulio Faggiano; Annamaria Colao
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-12       Impact factor: 4.553

2.  Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Yusuf Menda; Donghong Wang; Thomas M O'Dorisio; James R Howe
Journal:  J Surg Res       Date:  2014-05-21       Impact factor: 2.192

3.  Parenchyma-sparing surgery for pancreatic endocrine tumors.

Authors:  Fara Uccelli; F Gavazzi; G Capretti; M Virdis; M Montorsi; A Zerbi
Journal:  Updates Surg       Date:  2016-10-05

4.  Comparative analysis of colorectal mixed adenoneuroendocrine carcinoma and adenocarcinoma with neuroendocrine differentiation: a population-based study.

Authors:  Ling-Jun Song; Lin Yuan
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

5.  Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms.

Authors:  Zhiqiang Wang; Wenliang Li; Tianxing Chen; Jun Yang; Lilin Luo; Lianyu Zhang; Baocun Sun; Rui Liang
Journal:  Exp Ther Med       Date:  2015-07-13       Impact factor: 2.447

6.  Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching Analysis.

Authors:  Zhen Yang; Jie Liang; Kaiming Leng; Guangjun Shi
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

7.  Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.

Authors:  Nancy Sharma; Boris G Naraev; Eric G Engelman; M Bridget Zimmerman; David L Bushnell; Thomas M OʼDorisio; M Sue OʼDorisio; Yusuf Menda; Jan Müller-Brand; James R Howe; Thorvardur R Halfdanarson
Journal:  Pancreas       Date:  2017-02       Impact factor: 3.327

8.  Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Authors:  Allen B Choi; Jessica E Maxwell; Kendall J Keck; Andrew J Bellizzi; Joseph S Dillon; Thomas M OʼDorisio; James R Howe
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

9.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 10.  Zollinger-Ellison syndrome: recent advances and controversies.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Curr Opin Gastroenterol       Date:  2013-11       Impact factor: 3.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.